Moderna's mRNA Flu Vaccine Receives FDA Approval for Older Adults

The FDA has approved Moderna's mFlusiva, an mRNA-based seasonal influenza vaccine, for adults aged 50 and older. This marks the first mRNA flu vaccine to gain U.S. approval, representing a notable development in vaccine technology. Moderna expects to make it available for the 2026-2027 respiratory virus season.